Combined with in vivo efficacy studies in mice treated with APX2009 or Napa, these results with clinically tested Ref-1 and STAT3 inhibitors make the future translation of this work highly plausible for paediatric patients with MPNST. The gene discussed is STAT3; the disease is malignant peripheral nerve sheath tumor.